BioRem Inc.
BioRem Inc. (BIRMF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for BioRem Inc. (BIRMF), featuring income statements, balance sheets, and cash flow data.
BioRem Inc. (BIRMF) Income Statement & Financial Overview
Review BioRem Inc. BIRMF income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $4.73M | $9.32M | $14.89M | $7.30M |
| Cost of Revenue | $3.62M | $7.72M | $9.86M | $5.64M |
| Gross Profit | $1.11M | $1.60M | $5.02M | $1.66M |
| Gross Profit Ratio | $0.23 | $0.17 | $0.34 | $0.23 |
| R&D Expenses | $13988.00 | $7138.00 | $7944.00 | $13512.00 |
| SG&A Expenses | $1.02M | $1.30M | $1.99M | $1.13M |
| Operating Expenses | $1.02M | $1.31M | $1.99M | $1.14M |
| Total Costs & Expenses | $4.64M | $9.03M | $11.86M | $6.79M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $43582.00 | $46930.00 | $47429.00 | $50117.00 |
| Depreciation & Amortization | $134415.00 | $139966.00 | $184657.00 | $74829.00 |
| EBITDA | $228560.00 | $426542.00 | $3.21M | $587291.00 |
| EBITDA Ratio | $0.05 | $0.05 | $0.22 | $0.08 |
| Operating Income | $94145.00 | $286576.00 | $3.03M | $513070.00 |
| Operating Income Ratio | $0.02 | $0.03 | $0.20 | $0.07 |
| Other Income/Expenses (Net) | -$43582.00 | -$46930.00 | -$47429.00 | -$50117.00 |
| Income Before Tax | $50563.00 | $239646.00 | $2.98M | $462345.00 |
| Income Before Tax Ratio | $0.01 | $0.03 | $0.20 | $0.06 |
| Income Tax Expense | $13399.00 | $68910.00 | $790342.00 | $122521.00 |
| Net Income | $37164.00 | $170736.00 | $2.19M | $339824.00 |
| Net Income Ratio | $0.008 | $0.02 | $0.15 | $0.05 |
| EPS | $0.002 | $0.01 | $0.14 | $0.02 |
| Diluted EPS | $0.002 | -$0.02 | $0.12 | $0.02 |
| Weighted Avg Shares Outstanding | $18.58M | $16.14M | $15.80M | $15.70M |
| Weighted Avg Shares Outstanding (Diluted) | $18.58M | $15.66M | $18.58M | $18.52M |
Over the past four quarters, BioRem Inc. demonstrated steady revenue growth, increasing from $7.30M in Q2 2024 to $4.73M in Q1 2025. Operating income reached $94145.00 in Q1 2025, maintaining a consistent 2% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $228560.00, reflecting operational efficiency. Net income dropped to $37164.00, with EPS at $0.002. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan